{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:19:02Z","timestamp":1780046342722,"version":"3.53.1"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T00:00:00Z","timestamp":1401148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Forensic psychiatric settings contain a high prevalence of treatment-resistant violent schizophrenia patients. Clozapine therapy has the most robust data for the management of violence in patients with schizophrenia, but for those who cannot tolerate or refuse clozapine, high-dose antipsychotic treatment to high achieve high plasma levels remains a viable option despite limited evidence for efficacy in controlled trials. This article enumerates rational guidelines for employing high plasma level strategies, emphasizing the appropriate interpretation of, and reaction to high plasma antipsychotic levels in these treatment resistant patients, and the need to push treatment to the limits of tolerability or clinical response.<\/jats:p>","DOI":"10.1017\/s1092852914000236","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T09:00:05Z","timestamp":1401181205000},"page":"432-438","source":"Crossref","is-referenced-by-count":21,"title":["A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes"],"prefix":"10.1017","volume":"19","author":[{"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"S1092852914000236_ref34","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"S1092852914000236_ref29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ajp.149.4.500","article-title":"Haloperidol plasma levels and clinical response: a therapeutic window relationship","volume":"149","author":"Van Putten","year":"1992","journal-title":"Am J Psychiatry"},{"key":"S1092852914000236_ref14","first-page":"269","article-title":"Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance","volume":"29","author":"Simpson","year":"1968","journal-title":"Dis Nerv Syst"},{"key":"S1092852914000236_ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050277"},{"key":"S1092852914000236_ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.042895"},{"key":"S1092852914000236_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218d339"},{"key":"S1092852914000236_ref8","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900015947"},{"key":"S1092852914000236_ref19","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.48"},{"key":"S1092852914000236_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.622"},{"key":"S1092852914000236_ref38","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07638"},{"key":"S1092852914000236_ref4","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571100201X"},{"key":"S1092852914000236_ref35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852914000236_ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500406"},{"key":"S1092852914000236_ref20","first-page":"254","article-title":"Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia","volume":"19","author":"Midha","year":"1994","journal-title":"J Psychiatry Neurosci"},{"key":"S1092852914000236_ref23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301409"},{"key":"S1092852914000236_ref37","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.5.658"},{"key":"S1092852914000236_ref24","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182126d83"},{"key":"S1092852914000236_ref2","doi-asserted-by":"publisher","DOI":"10.1192\/apt.1.1.16"},{"key":"S1092852914000236_ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004924"},{"key":"S1092852914000236_ref3","first-page":"640","article-title":"Long-term high-dose neuroleptic treatment: who gets it and why?","volume":"44","author":"Krakowski","year":"1993","journal-title":"Hosp Community Psychiatry"},{"key":"S1092852914000236_ref32","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31811f394d"},{"key":"S1092852914000236_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000117424.05703.29"},{"key":"S1092852914000236_ref18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.152.4.650a","article-title":"Valproic acid effects on serum concentrations of clozapine and norclozapine","volume":"152","author":"Longo","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852914000236_ref15","unstructured":"Merck under license to Forest Pharmaceuticals. Saphris [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014."},{"key":"S1092852914000236_ref28","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000783"},{"key":"S1092852914000236_ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000361283.95962.d6"},{"key":"S1092852914000236_ref25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"S1092852914000236_ref6","volume-title":"Consensus Statement on High-Dose Antipsychotic Medication","year":"2006"},{"key":"S1092852914000236_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.144.1.25"},{"key":"S1092852914000236_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.03.015"},{"key":"S1092852914000236_ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hup.781"},{"key":"S1092852914000236_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181855cd6"},{"key":"S1092852914000236_ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200102000-00004"},{"key":"S1092852914000236_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182693d2a"},{"key":"S1092852914000236_ref36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.152.5.765","article-title":"Fluphenazine plasma levels, dosage, efficacy, and side effects","volume":"152","author":"Levinson","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852914000236_ref16","unstructured":"Sunovion Pharmaceuticals, Inc. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2013."},{"key":"S1092852914000236_ref31","first-page":"298","article-title":"A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy","volume":"57","author":"Wei","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852914000236_ref26","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181fb53c2"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852914000236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T19:53:14Z","timestamp":1555876394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852914000236\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1092852914000236"],"URL":"https:\/\/doi.org\/10.1017\/s1092852914000236","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}